Development of squamous cell carcinoma into basal cell carcinoma under treatment with Vismodegib

Journal of the European Academy of Dermatology and Venereology

Volumn 29, Issue 5, 2015, Pages 1006-1009

  Saintes, C ^a   Saint Jean, M ^a,b   Brocard, A ^a,b   Peuvrel, L ^a,b   Renaut, J J ^c   Khammari, A ^a,b   Quereux G ^a,b   Dreno B ^a,b  

^a HÔTEL DIEU   (France)

^b Team 12   (France)

^c Histopathology Institute   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; VISMODEGIB; ANILIDE; ANTINEOPLASTIC AGENT; PYRIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BASAL CELL CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURGERY; CASE REPORT; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MALE; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; SKIN BIOPSY; SQUAMOUS CELL CARCINOMA; TIME TO TREATMENT; TREATMENT RESPONSE; TUMOR BIOPSY; TUMOR DIFFERENTIATION; VERY ELDERLY; CARCINOMA, BASAL CELL; CHEMICALLY INDUCED; FACIAL NEOPLASMS; PATHOLOGY; SECOND CANCER; SKIN NEOPLASMS;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; FACIAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PYRIDINES; SKIN NEOPLASMS;

EID: 84928374013     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.12526     Document Type: Article

References (11)

1. Chren M-M, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ,. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol 2013; 133: 1188.
2. Ocanha JP, Dias JT, Miot HA, Stolf HO, Marques MEA, Abbade LPF,. Relapses and recurrences of basal cell face carcinomas. An Bras Dermatol 2011; 86: 386.
3. Johnson RL, Rothman AL, Xie J, et al.,. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 1996; 272: 1668.
4. Xie J, Murone M, Luoh SM, et al.,. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 1998; 391: 90.
5. Sekulic A, Migden MR, Oro AE, et al.,. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 2012; 366: 2171.
6. Aasi S,. New Onset of Keratoacanthomas After Vismodegib Treatment for Locally Advanced Basal Cell Carcinomas: a Report of 2 Cases. JAMA Dermatol 2013; 149: 242.
7. Iarrobino A, Messina JL, Kudchadkar R, Sondak VK,. Emergence of a squamous cell carcinoma phenotype following treatment of metastatic basal cell carcinoma with vismodegib. J Am Acad Dermatol 2013; 69: e33.
8. Orouji A, Goerdt S, Utikal J, Leverkus M,. Multiple highly and moderately differentiated squamous cell carcinomas of the skin during Vismodegib treatment of inoperable basal cell carcinoma. Br J Dermatol 2014 doi: 10.1111/bjd.12840. [Epub ahead of print]
9. Dubey AK, Dubey S, Handu S, Qazi M,. Vismodegib: the first drug approved for advanced and metastatic basal cell carcinoma. J Postgrad Med 2013; 59: 48.
10. Martin RC II, Edwards MJ, Cawte TG, Sewell CL, McMasters KM,. Basosquamous carcinoma: analysis of prognostic factors influencing recurrence. Cancer 2000; 88: 1365.
11. Bowman PH, Ratz JL, Knoepp TG, Barnes CJ, Finley EM,. Basosquamous carcinoma. Dermatol Surg 2003; 29: 830. discussion 833.